SOURCE: BioMedReports


June 16, 2011 07:01 ET

Small Biotech Company With Significant Potential Now Has FDA Trade Catalyst in Play

LOS ANGELES, CA--(Marketwire - Jun 16, 2011) - On Wednesday, a small Seattle based biotech firm called TapImmune Inc. (OTCBB: TPIV) filed an SEC form 8-K, Regulation FD Disclosure which quietly revealed that an investigative new drug application ("IND") for a Phase I clinical trial on a set of Her2/neu breast cancer antigens that the company has the exclusive option to license after Phase I studies has been filed.

While the company's TAP platform presents multiple shots on goal for biotech speculators, Dr. Glynn Wilson Ph.D., Exec. Chairman and Chief Exec. Officer of the company explains what this development means and why the filing of this particular IND represents an important step for his firm.

A special report about what this development could mean to biotech investors and breast cancer patients who express HER-2/neu (human epidermal growth factor receptor 2) is available now at:

In addition, investors interested in making more profitable trades can access BioMedReports' new Complete Database of Clinical Trials and Upcoming FDA and World-Wide Regulatory Decisions at:

News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556